Moodle at CCNM

The purpose of this presentation is to allow the attendee a chance to “catch up” after a full day of genomic presentations and get an introduction to the day’s material. Dr. Anderson presents several case studies on patients he has managed. A “1-2-3” approach will be presented which outlines how practitioners can “troubleshoot” the treatment issues that happen when either the patient “self-treats” or has an unusual reaction to a nutrigenomic therapy.  Pharmaceuticals discussed in case presentations will include Deplin, Metanx, Buproprion, and Diphenhydramine.

How do the three phases of detoxification work? How do pharmaceuticals affect them? A common area of misunderstood reactivity is sulfite oxidation, which often is mistaken for a Type-1 histamine reaction. This session is designed to give clarity to the signs of these reactions as well as prevention and treatment strategies. Phase-2 is dominated by Glutathione and Glycine but also these “back-up” hydroxyl reduction in Phase-1. How do pharmaceuticals affect these supports, how clinically can we assess and support them and what does it look like clinically when they are overwhelmed? Additional case studies are discussed. Pharmaceuticals discussed in case presentations will include Mucomyst, Succimer, acetaminophen, codeine, ciclosporin and diazepam.

Genomic topics have exploded in the past decade to the point that misinformation and confusion are as possible between practitioner and patient as clarity. Dr. Anderson will use his background in genomic research, clinical genomics and troubleshooting to outline the most clinically salient portions of genomics as they relate to fertility, birthing and pediatrics. The goal of the talk is to leave the attendee with understanding as well as clinical tools to “sort out” these critical topics. And although the last baby Dr. Anderson delivered is 23 years old he has maintained a practice long involvement in high risk prenatal care, fertility and pediatrics.

This 12-hour six-part series breaks down this enormous topic of genomic medicine into portions that any clinician can use to understand and incorporate this vast topic into their practice. The goal of this format is to use each session to build a progressive understanding of the topics involved while having time to process and implement the information.

What are the basics of “cause” in the areas of agitation and sleep problems. What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous GABA, Glycine and other calming neurotransmitters benefit and refine your therapies?  What are the basics of “cause” in the areas of depression? What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous serotonin, dopamine and norepinephrine neurotransmitters benefit and refine your therapies?  How does the brain become inflamed and how does that affect neuropsychiatric status? What genomic and nutrigenomic factors can alter this status and restore the brain to a non-inflamed state?  Dr. Anderson discusses case studies that he has worked through in neuro-psychiatric conditions and how they played out. The goal of these cases is to illustrate how genomic assessment and nutrigenomics cross over pharmacology and how they can be implemented clinically.

Dr. Anderson reviews and synthesizes all of the content from the prior three presentations. Guidelines are presented for practitioners who are just starting out with pharmacogenomics and other forms of genetic testing. Practitioners are given advice on how to get started, how to avoid feeling overwhelmed, and what their top priorities should be for integrating these practices in their clinic.